Vaxart
American biotechnology company
Vaxart, Inc. is an American biotechnology company focused on developing oral vaccines administered by tablet rather than by injection. The company is headquartered in South San Francisco, California.
History[edit]
Vaxart was founded in 2004 by Sean Tucker, who was a graduate student at the time. The company initially focused on developing vaccines for influenza and other respiratory viruses. In 2018, Vaxart became a publicly traded company through a reverse merger with Aviragen Therapeutics.
Technology[edit]
Vaxart's technology platform is based on the use of adenovirus vectors to deliver vaccine antigens in a tablet form. This approach aims to stimulate both systemic and mucosal immune responses, potentially offering advantages over traditional injectable vaccines. The oral delivery system is designed to be more convenient and accessible, especially in areas with limited healthcare infrastructure.
Research and Development[edit]
Vaxart has been involved in the development of vaccines for a variety of infectious diseases, including influenza, norovirus, and COVID-19. In 2020, the company announced that it was working on an oral COVID-19 vaccine candidate. The vaccine entered clinical trials, and Vaxart has been exploring partnerships to advance its development.
COVID-19 Vaccine[edit]
In response to the COVID-19 pandemic, Vaxart developed an oral vaccine candidate, VXA-CoV2-1. The vaccine is designed to be stable at room temperature, which could simplify distribution and administration. Early clinical trials have been conducted to assess its safety and immunogenicity.
Partnerships and Collaborations[edit]
Vaxart has collaborated with various organizations to advance its vaccine candidates. The company has received funding from the Biomedical Advanced Research and Development Authority (BARDA) and has partnered with other biotechnology firms to enhance its research capabilities.
Controversies[edit]
In 2020, Vaxart faced scrutiny over its claims of being selected for the U.S. government's Operation Warp Speed program. The company later clarified that it was not directly funded by the program but was involved in preliminary studies.
Related pages[edit]
References[edit]
-
Vaxart Corporate 2022 Logo
-
Vaxart Headquarters
-
Vaxart Corporate 2022 Logo
-
Vaxart Headquarters
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
